Pregnancy Can Accelerate Retinopathy, but the “Riskiest Trimester” May Be a Myth

Pregnancy can accelerate diabetic eye disease, but is one trimester more dangerous than another? A 2026 retrospective study examining diabetic retinopathy during pregnancy found that retinal damage could develop or worsen at any stage, with no statistically significant differences in progression between trimesters. These findings suggest clinicians should focus less on identifying a single high-risk trimester and more on individual patient risk, baseline retinal health, and continuous monitoring.

Table of Contents

1. New Study Challenges Trimester-Specific Retinopathy Risk
2. Why Baseline Retinal Health Matters More
3. Personalized Retinal Screening During Pregnancy
4. Clinical Implications for Diabetes Care
5. Conclusion
6. Frequently Asked Questions

New Study Challenges Trimester-Specific Retinopathy Risk

Researchers evaluated whether the risk of diabetic retinopathy progression changed across pregnancy stages. The 2026 study published in the Journal of Vitreoretinal Diseases followed 158 women with diabetes using clinical information from before pregnancy, each trimester, and after delivery.

Overall, 13 patients, representing 8.2% of the cohort, experienced worsening retinopathy during pregnancy. Progression rates differed numerically across the observation periods, but those differences were not statistically significant.

Reported progression rates were 6.9% in the prepregnancy and first-trimester interval, 5.0% in the second trimester, and 14.3% in the third trimester. Additionally, 10.0% experienced progression during the postpartum observation period. The comparison across trimesters produced a P value of .42.

Among patients without retinopathy at baseline, new disease appeared in 4.62%, 7.69%, and 5.88% across the three pregnancy intervals. Postpartum manifestation occurred in 6.45%. Again, differences were not statistically significant, with a P value of .97.

Although the third-trimester progression percentage appeared higher, the findings do not establish that this period carries greater risk. Importantly, the absence of statistical significance does not prove that all trimesters have identical risks.

Because this was a single-center retrospective study, the results also require confirmation in larger prospective populations.

Nevertheless, the findings challenge the idea that retinal surveillance should concentrate primarily on one stage of pregnancy. Instead, diabetic eye disease deserves attention throughout gestation.

Why Baseline Retinal Health Matters More

During pregnancy, changes in blood sugar, blood pressure, and circulation may affect the retina. However, existing evidence suggests that the condition of the retina before conception may be especially important.

Previous research has identified baseline retinopathy as a major predictor of progression. Women with existing retinal disease face a greater risk of worsening than those whose retinal examinations show no diabetic damage before pregnancy.

Other clinical factors also deserve consideration. Longer diabetes duration, elevated blood pressure, and suboptimal glucose management have been associated with retinal complications in previous research.

Furthermore, rapid improvements in blood glucose can sometimes produce temporary worsening of existing retinopathy. This phenomenon is particularly relevant when patients intensify diabetes treatment before conception or during early pregnancy.

However, these findings should not discourage appropriate glucose management. Maintaining recommended glucose targets remains essential for maternal and fetal health.

Early identification of retinal abnormalities helps clinicians intervene before permanent vision loss occurs. For this reason, retinal evaluations should be part of routine preconception care for women with preexisting diabetes.

Therefore, understanding baseline retinal status may provide greater clinical value than relying solely on gestational timing. For patients with preexisting retinal disease, early assessment also creates an opportunity to plan closer follow-up throughout pregnancy.

Personalized Retinal Screening During Pregnancy

These findings support more personalized eye care, but they do not change current screening recommendations.

According to the American Diabetes Association's 2026 Standards of Care, individuals with preexisting type 1 or type 2 diabetes should receive an eye examination before pregnancy and during the first trimester.

Additional examinations may be needed every trimester and for up to one year postpartum, depending on retinopathy severity and the eye care professional's recommendations.

Therefore, clinicians should use initial retinal findings and individual risk factors to guide follow-up appointments.

Patients with moderate or worse nonproliferative retinopathy, proliferative retinopathy, or diabetic macular edema require prompt specialist assessment.

Optical coherence tomography can also help evaluate suspected macular edema. Meanwhile, retinal photography may support documentation, although it does not replace a comprehensive eye examination when clinically indicated.

Symptoms such as sudden blurred vision, new floaters, or abrupt vision loss warrant urgent ophthalmic evaluation.

Importantly, gestational diabetes alone generally does not require additional retinopathy screening when there is no preexisting diabetes.

The goal is not to schedule more eye exams for everyone. Rather, clinicians should tailor retinal surveillance to each patient's findings, diabetes history, and changing medical condition.

Clinical Implications for Diabetes Care

These findings on diabetic retinopathy during pregnancy reinforce the importance of coordinated care among endocrinologists, obstetric clinicians, and ophthalmologists.

First, retinal assessment should become a routine part of preconception counseling for patients with established diabetes. Identifying advanced disease before pregnancy allows clinicians to consider treatment and arrange appropriate follow-up.

Second, retinal monitoring should continue throughout pregnancy rather than concentrating on a presumed high-risk trimester.

Third, clinicians should review glucose trends, blood pressure, diabetes duration, and previous retinal findings when determining follow-up needs.

Furthermore, patients undergoing rapid glucose improvement may benefit from additional retinal assessment, particularly when retinopathy already exists.

Treatment decisions also require careful coordination. Laser photocoagulation remains an option for certain vision-threatening retinal conditions during pregnancy.

However, anti-vascular endothelial growth factor medications require particular caution because of potential fetal risks and limited pregnancy safety data. Clinicians must weigh potential benefits against risks when considering these treatments.

Finally, postpartum follow-up should not be overlooked. Retinal changes may continue after delivery, making continuity of care important even when pregnancy-related appointments end.

Conclusion

The 2026 study raises an important question about monitoring diabetic retinopathy during pregnancy: should clinicians focus more on gestational timing or each patient's individual risk factors?

Current evidence supports careful assessment of baseline retinal disease and ongoing monitoring throughout pregnancy. Although retinal progression occurred in the study, no trimester showed a statistically significant increase in risk.

Therefore, the clinical priority remains early screening, individualized follow-up, effective diabetes management, and timely ophthalmology referral.

Ultimately, recognizing the patient's retinal risk profile may help protect vision more effectively than assuming one trimester is inherently more dangerous.

Frequently Asked Questions

1. Can pregnancy make diabetic retinopathy worse?

Yes. Pregnancy can accelerate existing diabetic retinopathy, particularly in patients with advanced baseline disease, long-standing diabetes, or challenging glucose management. However, progression does not occur in every patient.

2. Which trimester carries the highest risk of retinopathy progression?

A 2026 retrospective study found no statistically significant difference in retinal progression across trimesters. Larger studies are needed before concluding that trimester-related risk is equivalent.

3. How often should pregnant patients with diabetes receive retinal examinations?

Patients with preexisting type 1 or type 2 diabetes should undergo examination before pregnancy and during the first trimester. Further monitoring every trimester and through the first postpartum year depends on retinal findings and specialist recommendations.

4. Does improving blood glucose rapidly worsen diabetic retinopathy?

Rapid glucose improvement can temporarily worsen existing retinal disease in some patients. Nevertheless, appropriate glucose control remains essential, and closer retinal monitoring may help identify early changes.

5. Is retinal screening necessary for gestational diabetes?

Gestational diabetes alone generally does not increase short-term retinopathy risk enough to require pregnancy-specific retinal screening. However, patients with previously diagnosed diabetes should follow established ophthalmic monitoring recommendations.

Disclaimer: This content is not medical advice. For any health issues, always consult a healthcare professional. In an emergency, call 911 or your local emergency services.